{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:31:26Z","timestamp":1790130686536,"version":"4.0.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.dld.2018.10.024","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T12:21:55Z","timestamp":1550578915000},"page":"967-971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Real-world efficacy of adalimumab and infliximab for refractory intestinal Beh\u00e7et\u2019s disease"],"prefix":"10.1016","volume":"51","author":[{"given":"Naomi","family":"Sugimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Mizoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shozo","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokatsu","family":"Miyaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tanida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2018.10.024_bib0005","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00535-013-0872-4","article-title":"The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet\u2019s disease: indication of anti-TNFalpha monoclonal antibodies","volume":"49","author":"Hisamatsu","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.dld.2018.10.024_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.08.042","article-title":"Adalimumab for the treatment of Japanese patients with intestinal Behcet\u2019s disease","volume":"13","author":"Tanida","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2018.10.024_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2017.377","article-title":"Updated treatment strategies for intestinal Behcet\u2019s disease","volume":"33","author":"Park","year":"2018","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.dld.2018.10.024_bib0020","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/ibd.20457","article-title":"Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet\u2019s disease","volume":"14","author":"Naganuma","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2018.10.024_bib0025","doi-asserted-by":"crossref","first-page":"e3863","DOI":"10.1097\/MD.0000000000003863","article-title":"Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study","volume":"95","author":"Hibi","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.dld.2018.10.024_bib0030","doi-asserted-by":"crossref","first-page":"687257","DOI":"10.1155\/2014\/687257","article-title":"Adalimumab treatment in biologically naive Crohn\u2019s disease: relationship with ectopic MUC5AC expression and endoscopic improvement","volume":"2014","author":"Mizoshita","year":"2014","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.dld.2018.10.024_bib0035","doi-asserted-by":"crossref","first-page":"e7800","DOI":"10.1097\/MD.0000000000007800","article-title":"Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy","volume":"96","author":"Mizoshita","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.dld.2018.10.024_bib0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10238-004-0033-4","article-title":"Behcet\u2019s disease","volume":"4","author":"Suzuki Kurokawa","year":"2004","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.dld.2018.10.024_bib0045","first-page":"1078","article-title":"Criteria for diagnosis of Behcet\u2019s disease. International Study Group for Behcet\u2019s Disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2018.10.024_bib0050","first-page":"1833","article-title":"Efficacy of infliximab in intestinal Behcet\u2019s disease: a Korean multicenter retrospective study","volume":"19","author":"Lee","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2018.10.024_bib0055","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ecco-jcc\/jjv052","article-title":"Internet-orientated assessment of QOL and actual treatment status in Japanese patients with inflammatory bowel disease: the 3I survey","volume":"9","author":"Matsumoto","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2018.10.024_bib0060","first-page":"301","article-title":"Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Behcet\u2019s disease","volume":"9","author":"Karube","year":"2016","journal-title":"Int Med Case Rep J"},{"key":"10.1016\/j.dld.2018.10.024_bib0065","doi-asserted-by":"crossref","first-page":"395","DOI":"10.5217\/ir.2017.15.3.395","article-title":"Long-term safety and efficacy of adalimumab for intestinal Behcet\u2019s disease in the open label study following a phase 3 clinical trial","volume":"15","author":"Inoue","year":"2017","journal-title":"Intest Res"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865819300891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865819300891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:09:20Z","timestamp":1761624560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865819300891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1590865819300891"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2018.10.024","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world efficacy of adalimumab and infliximab for refractory intestinal Beh\u00e7et\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2018.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}